77 | Azra Raza on The Way We Should Fight Cancer

Episode Summary

Executive Summary: Sean Carroll interviews oncologist Azra Raza about her book The First Cell, arguing that cancer care over-focuses on treating late-stage disease with toxic, outdated methods and under-invests in early detection and prevention. Raza emphasizes patient stories, the human and financial costs of current oncology, and a vision for multi-modal screening, biomarkers, and longitudinal tissue studies to catch cancer at its earliest, most treatable stage.

Main Topics: Cancer as a silent, evolving disease: Raza explains cancer as a rogue, immortalized cell population that accumulates mutations, evolves over time, and becomes increasingly heterogeneous and harder to treat, making late-stage disease especially difficult. The human cost of oncology: A central theme is the suffering of patients and families, including Raza’s own husband and young patients like Andrew, highlighting that cancer is not just a biological problem but an emotional and moral one. Critique of current treatment paradigms: Raza argues that surgery, chemotherapy, and radiation remain the dominant tools despite decades of limited progress for advanced cancers, often causing severe toxicity with little benefit for many patients. Early detection and prevention as the priority: She advocates shifting major resources from chasing the last cancer cell to finding the first cell, using screening, liquid biopsy, biomarkers, and continuous monitoring technologies. Limits of animal models and clinical trial design: Raza contends that mouse models and artificial preclinical systems often fail to predict human outcomes and that trials should be redesigned around human tissues, responder/non-responder analysis, and better biomarker enrichment. A longitudinal tissue repository as a research engine: She describes her uniquely large biobank of serial patient samples, built over decades, as the basis for studying progression from pre-leukemia to leukemia and identifying risk and early disease signatures. Ethics, mortality, and dignity in death: The conversation closes with a philosophical and ethical discussion about accepting mortality, avoiding denial, and recognizing the courage of patients facing death with grace.

Key Arguments: Cancer is best understood as a constantly evolving, mutated cell population rather than a single fixed disease; by the time it is advanced, it may bear little resemblance to its origin. Most current oncology still relies on surgery, chemotherapy, and radiation, which cure many early cancers but leave advanced cancers with outcomes no better than decades ago. The medical system is overly focused on eradicating visible or residual disease instead of detecting malignancy at its earliest stage, when cure rates are much higher. Early detection technologies such as liquid biopsy, biomarker detection, imaging, and wearable/implantable sensors could identify cancer before it becomes deadly. Mouse and petri-dish models are useful for basic biology, but they are poor predictors of whether a drug will work in humans, especially for cancer drug development. Clinical trials should preserve and deeply analyze patient samples so researchers can learn why some people respond and many do not, then enrich future trials for likely responders. Cancer care has substantial financial toxicity; many patients are harmed not only physically but economically by expensive therapies with low probability of benefit. Patient stories should remain central to cancer research and policy because the disease’s human burden is inseparable from the science. A major research investment should go to prevention and early detection, not just treatment of advanced disease. Longitudinal human tissue biobanks provide a better path to understanding progression from early abnormality to full cancer than creating more animal models.

Data Points: U.S. heart disease and cancer mortality ranking: Two leading causes of death - Carroll opens by noting that heart disease and cancer are the top causes of death in the United States. Cancers cured today: 68% - Raza says roughly 68% of diagnosed cancers are cured with current approaches. Cancers not cured today: 32% - She says the remaining 32% have outcomes as bad as they did decades ago. Early-stage cancer cure rate: 90% - Raza states that patients diagnosed with early-stage disease can often be cured. Advanced-stage cancer mortality: 90% or more die - She contrasts early-stage success with the grim prognosis of advanced common cancers. New adult cancer cases in the U.S.: 1.7 million per year - Raza cites annual adult cancer incidence in America. New childhood cancer cases in the U.S.: 14,000 per year - She notes the much smaller but significant pediatric cancer burden. Cancer mortality decline over 30 years: 26% - She attributes the decline mainly to anti-smoking efforts and screening, not major drug breakthroughs. Current annual decline in cancer mortality: 1% per year - Raza says progress has slowed because screening and existing therapies are nearing their limits. Financial ruin among cancer patients: 42% - She says 42% of individuals diagnosed with cancer become financially ruined over two-plus years. Targeted therapy example: Imatinib for chronic myeloid leukemia - Used as a model of a successful single-target drug in a rare setting. Chemotherapy regimen mentioned: 7 and 3 - Raza says she has used the same acute myeloid leukemia regimen from 1977 to 2019. Patient sample repository size: More than 60,000 samples - She describes her biobank of longitudinal patient tissues and blood samples. Repository maintenance cost: Almost $1 million per year - She says maintaining the tissue repository requires substantial annual funding. Proteomics cost for 200 patients: $4 million - Raza gives a concrete example of the expense of large-scale molecular analysis. Human genome sequencing cost/time comparison: From 2.7 billion dollars and 15 years to a few thousand dollars and 3 weeks - Used to illustrate how rapidly genomic technology has improved. Cancer survivor incidence of new cancers: 1 in 5 - She says one in five new cancers is diagnosed in someone who is already a cancer survivor. Hybrid resource allocation proposal: 50/50 split - Raza argues for dividing resources equally between present patients and future prevention/early detection. Current resource allocation estimate: 5% future patients / 95% present treatment - She claims the current system overwhelmingly favors late-stage treatment over prevention.

Pivotal Quotes: "This is not a book about cancer. It is about cancer patients." — Azra Raza: She explains the purpose of her book and why patient experience must remain central. "Dying is not a failure. Denying death is a failure." — Azra Raza: She argues for honesty and dignity in facing terminal illness rather than treating death as medical defeat. "We have to stop hurting them." — Azra Raza: Her core ethical critique of current cancer treatment, especially when benefit is low and toxicity is high.

Implications: If Raza’s view gains traction, oncology may shift toward earlier detection, biomarker-driven personalization, and human tissue-based research, while reducing reliance on toxic one-size-fits-all treatments. This could improve outcomes, lower costs, and change how society thinks about dying with cancer.